Compare Carlyle Group Inc (CG) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carlyle Group Inc vs CVS Health Corp — how do they compare? Carlyle Group Inc trades at $44.23 (market cap $16.37B), while CVS Health Corp trades at $104.32 (market cap $135.48B). The key difference: CVS Health Corp is far larger — about 8.3× Carlyle Group Inc's market cap, and Carlyle Group Inc pays the higher dividend (3.08%). Which is the better fit depends on your goals.
| CG | CVS | |
|---|---|---|
Market Cap | $16.37B | $135.48B |
Sector | Financials | Health |
52-Week High | $69.35 | $106.18 |
52-Week Low | $40.52 | $58.75 |
Dividend Yield | 3.08% | 2.51% |
Enterprise Value | — | $202.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CG trades at $44.14, down 1.27% on the day, with a neutral technical signal and bearish moving averages. The company reported revenue of $3.21B and net income of $808.70M for 2025, with a P/E ratio of 30.24. Recent developments include the acquisition of a majority stake in MAI Capital Management and the upcoming Q2 2026 earnings release on August 5, 2026.
The outlook is mixed, with analyst consensus leaning bullish (53.84% Buy) and a price target of $58.57 implying significant upside. However, risks include volatile cash flows from operations, recent earnings misses, and a high valuation. The stock's performance hinges on successful execution of growth initiatives and improved earnings consistency.
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
